U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H14FNO3
Molecular Weight 275.275
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBAFLOXACIN

SMILES

CC1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C

InChI

InChIKey=DXKRGNXUIRKXNR-UHFFFAOYSA-N
InChI=1S/C15H14FNO3/c1-7-3-4-9-8(2)12(16)5-10-13(9)17(7)6-11(14(10)18)15(19)20/h5-7H,3-4H2,1-2H3,(H,19,20)

HIDE SMILES / InChI

Molecular Formula C15H14FNO3
Molecular Weight 275.275
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Ibafloxacin is a fluoroquinolone antibiotic drug used in veterinary medicine. Ibafloxacin, a fluorinated 4-quinolone, is a broad spectrum antibiotic with bactericidal action against Gram-positive and Gram-negative bacteria. Ibafloxacin is presented in the form of a tablet/oral gel containing a racemic mixture of S- and R-ibafloxacin. The antimicrobial activity of the racemate originates mainly from the S-enantiomer. Ibafloxacin was marketed under the brand name Ibaflin. Ibaflin tablets were intended for use in dogs for treatment of respiratory tract infections, urinary tract infections and dermal infections caused by ibafloxacin susceptible pathogens. Ibafloxacin, is an antibiotic belonging to the class ‘fluoroquinolones’. It works by blocking an enzyme called ‘DNA gyrase’, which is important in allowing bacteria to make copies of their DNA. This enzyme is only found in bacterial cells, and does not have a similar function in animal cells. By blocking DNA gyrase, ibafloxacin prevents the bacteria from making DNA and stops them making proteins and growing, resulting in their death.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Ibaflin

Approved Use

Dogs-tablets: Dermal tissue infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible strains of Staphylococci, E. coli and Proteus mirabilis Acute, uncomplicated urinary tract infections (acute) caused by susceptible strains of Staphylococci, Proteus spp., Enterobacter spp., E. coli and Klebsiella spp. Respiratory tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and Klebsiella spp. Cats-oral gel Dermal infections (soft tissue infections – wounds, abscesses) caused by susceptible pathogens such as staphylococci, E. coli, Proteus spp. and Pasteurella spp. Respiratory tract infections (upper or lower tract) caused by susceptible pathogens such as Staphylococcus spp., E. coli, Klebsiella spp. and Pasteurella spp.

Launch Date

2000
Curative
Ibaflin

Approved Use

Dogs-tablets: Dermal tissue infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible strains of Staphylococci, E. coli and Proteus mirabilis Acute, uncomplicated urinary tract infections (acute) caused by susceptible strains of Staphylococci, Proteus spp., Enterobacter spp., E. coli and Klebsiella spp. Respiratory tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and Klebsiella spp. Cats-oral gel Dermal infections (soft tissue infections – wounds, abscesses) caused by susceptible pathogens such as staphylococci, E. coli, Proteus spp. and Pasteurella spp. Respiratory tract infections (upper or lower tract) caused by susceptible pathogens such as Staphylococcus spp., E. coli, Klebsiella spp. and Pasteurella spp.

Launch Date

2000
Curative
Ibaflin

Approved Use

Dogs-tablets: Dermal tissue infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible strains of Staphylococci, E. coli and Proteus mirabilis Acute, uncomplicated urinary tract infections (acute) caused by susceptible strains of Staphylococci, Proteus spp., Enterobacter spp., E. coli and Klebsiella spp. Respiratory tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and Klebsiella spp. Cats-oral gel Dermal infections (soft tissue infections – wounds, abscesses) caused by susceptible pathogens such as staphylococci, E. coli, Proteus spp. and Pasteurella spp. Respiratory tract infections (upper or lower tract) caused by susceptible pathogens such as Staphylococcus spp., E. coli, Klebsiella spp. and Pasteurella spp.

Launch Date

2000
PubMed

PubMed

TitleDatePubMed
In-vitro activity of seventeen antimicrobial compounds against seven species of mycobacteria.
1988 Dec
Pharmacokinetics of ibafloxacin following intravenous and oral administration to healthy Beagle dogs.
2002 Apr
In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin.
2002 Dec
Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles.
2004 Jun
Pharmacokinetics of ibafloxacin in healthy cats.
2005 Feb
Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats.
2005 Feb
Clinical efficacy of two ibafloxacin formulations in the treatment of canine pyoderma.
2006 Feb 18
Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats.
2007 Jan
Development of a method for the determination of ibafloxacin in plasma by HPLC with flourescence detection and its application to a pharmacokinetic study.
2007 May-Jun
Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats.
2007 Nov
Patents

Patents

Sample Use Guides

Oral use, 15 mg ibafloxacin/kg once daily. The duration of treatment depends on the nature and severity of the infection and on the response. In most cases, a 10-day treatment course will be sufficient.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Ibafloxacin had good activity against Pasteurella spp., Escherichia coli, Klebsiella spp., Proteus spp. and Staphylococcus spp. (MIC90=0.5 ug/mL), moderate activity against Bordetella bronchiseptica, Enterobacter spp. and Enterococcus spp. (MIC50=4 ug/mL) and low activity against Pseudomonas spp. and Streptococcus spp. https://www.ncbi.nlm.nih.gov/pubmed/12485346
Escherichia coli and Pasteurella, Klebsiella and Staphylococcus spp. are commonly isolated from feline infections and all are susceptible to ibafloxacin (MIC90 < or = 0.5 ug/mL)
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:25:32 GMT 2023
Edited
by admin
on Fri Dec 15 16:25:32 GMT 2023
Record UNII
53VPK9R0T5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBAFLOXACIN
INN   MART.   MI   USAN  
INN   USAN  
Official Name English
IBAFLOXACIN [MART.]
Common Name English
IBAFLOXACIN [MI]
Common Name English
R 835
Code English
ibafloxacin [INN]
Common Name English
1H,5H-BENZO(IJ)QUINOLIZINE-2-CARBOXYLIC ACID, 9-FLUORO-6,7-DIHYDRO-5,8-DIMETHYL-1-OXO-
Common Name English
S 25930
Code English
IBAFLIN
Brand Name English
9-Fluoro-6,7-dihydro-5,8-dimethyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid
Systematic Name English
R-835
Code English
IBAFLOXACIN [EMA EPAR VETERINARY]
Common Name English
S-25930
Code English
IBAFLOXACIN [USAN]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01MA96
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
EMA VETERINARY ASSESSMENT REPORTS IBAFLIN [WITHDRAWN]
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
NCI_THESAURUS C795
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
EMA VETERINARY ASSESSMENT REPORTS IBAFLIN [WITHDRAWN]
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
Code System Code Type Description
CAS
91618-36-9
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
MERCK INDEX
m6181
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY Merck Index
USAN
AA-19
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
NCI_THESAURUS
C83772
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
INN
6398
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
FDA UNII
53VPK9R0T5
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
WIKIPEDIA
IBAFLOXACIN
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL170052
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
SMS_ID
100000083665
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID8057853
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
EVMPD
SUB08091MIG
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
PUBCHEM
71186
Created by admin on Fri Dec 15 16:25:32 GMT 2023 , Edited by admin on Fri Dec 15 16:25:32 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY